Sunil Verma, MD
As costs continue to trend upward in oncology, a comprehensive plan must be established so that patients with cancer can continue to receive systemic therapy, said Sunil Verma, MD.
, Verma shared insight on the benefits and unanswered questions that remain with biosimilars in oncology.
OncLive: What impact would the implementation of biosimilars have?
: There are a couple aspects to look at when we talk about global impact. One would be the cost of care. The second would be the integration of these new agents. In terms of cost of care, introducing biosimilars would reduce the burden of cost that's becoming an issue all over the world. This is especially true for biologic agents in cancer. The numbers [for biosimilar costs] are quite durable between what we've seen in North America and what we see across to Europe. Depending on what kind of cost reductions we get, this would have a significant impact.
... to read the full story